Novo Nordisk tells Europe weight-loss drug will save money as well as lives:
Novo Nordisk aims to convince Europeans governments to pay for its obesity drug ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-address-social-inequality-dialogue-with-healthcare-systems-ceo-2023-08-25/
Photo: reuters.com · view article
Novo Nordisk seeks European reimbursement for WegovyCEO Lars Fruergaard Jorgensen stressed medical and cost benefits to Europe’s public health systems on August 25.
Key FactsAug 25, 2023 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- CEO Lars Fruergaard Jorgensen seeks reimbursement for patients with the highest BMI and comorbidities, and possibly socioeconomic disadvantage.
- Alongside dietary and exercise changes, Wegovy produces average weight loss of around 15 percent.
- Jorgensen said serving a potential worldwide market of around one billion patients could take several years.
- Wegovy is available in Germany, Norway and Denmark, while Jorgensen announced further launches without naming countries or timing.
In Europe, we would aim to seek reimbursement for those patients with the highest BMI, have co-morbidities, and perhaps also those less fortunate from a socio-economic point of view," he told a Reuters Newsmaker event, adding such people were often "among those who consume the highest cost in healthcare systems."— Lars Fruergaard Jorgensen, Novo Nordisk CEO, speaking at a Reuters Newsmaker event
Story Details
| Last Updated | |
| Total Articles | 10 |
Main Topics
News on this topic
Weight-Loss Drug Wegovy Will Launch In More Countries Despite Ongoing Struggles Over Stellar Demand, CEO Says
forbes.com/sites/roberthart/2023/08/25/weight-loss-drug-wegovy-will-launch-in-more-countries-despite-ongoing-struggles-over-stellar-demand-ceo-says/
Reuters Newsmaker Interview with Lars Fruergaard Jørgensen: Reuters Newsmaker Interview with Lars Fruergaard Jørgensen - - Friday, August 25, 2023
events.reutersevents.com/reuters/newsmaker/LarsFruergaardJorgensen
Similar to This
Previous
Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
qz.com/novo-nordisk-cagrisema-women-weight-loss-analysis-102026
US competitor of Novo Nordisk: Eli Lilly's diet pill receives EU approval: So far, the Danish pharmaceutical company Novo Nordisk has been the only ...
manager-magazin.de/unternehmen/abnehmpille-von-eli-lilly-erhaelt-gruenes-licht-der-eu-a-ecdd2ad4-219f-4885-a05c-bf4f41b55c1f
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
OpinionNovo CEO urges staff to embrace more customer-focused culture: Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused ...
reuters.com/legal/litigation/novo-ceo-urges-staff-embrace-more-customer-focused-culture-2026-09-15/
Obesity battle heats up again as Novo claws way back into race with Lilly: Novo Nordisk investors have found little cause for optimism during a bruising two-year ...
reuters.com/legal/litigation/obesity-battle-heats-up-again-novo-claws-way-back-into-race-with-lilly-2026-08-03/
U.S. employers dropping GLP-1 weight loss drug coverage in 2027
dlvr.it/TSzyx9
Novo Nordisk's weight loss pill is hitting 3 million U.S. prescriptions — and most users had never tried one before
qz.com/novo-nordisk-wegovy-pill-3-million-prescriptions-060826
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
cnbc.com/2026/06/08/novo-nordisk-eli-lilly-obesity-pills-medicare-coverage.html
Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees: Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo ...
reuters.com/world/cigna-drops-coverage-glp-1-obesity-drugs-its-own-employees-2026-06-02/
EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug: COPENHAGEN — Novo Nordisk has obtained approval for the pill form of its popular ...
koreatimes.co.kr/world/20260522/eu-regulator-approves-pill-form-of-novo-nordisks-wegovy-weight-loss-drug
Novo Nordisk’s next obesity battlefront: Winning beyond America: The weight loss pill had a strong U.S. launch this year, and Novo believes that will be ...
cnbc.com/2026/05/18/novo-nordisk-wegovy-pill-launch-eli-lilly-foundayo-weight-loss.html
France fines drug firms €1.7m over adverts for Mounjaro and Wegovy: France's medicine safety agency ANSM said on Monday it had imposed fines on pharmaceutical ...
thelocal.fr/20260504/france-fines-drug-firms-e1-7m-over-adverts-for-mounjaro-and-wegovy
Novo Nordisk says Wegovy shows greater weight loss than Eli Lilly's rival pill: A cross-trial comparison shows Novo's oral semaglutide produced 3 ...
qz.com/wegovy-foundayo-weight-loss-novo-nordisk
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html
Pill vs. shot: Cost and convenience reshape the weight loss drug market: Americans starting weight-loss medicines for the first time want lower cost and greater ...
reuters.com/business/healthcare-pharmaceuticals/americans-want-weight-loss-pills-cost-convenience-2026-04-06/
Foundayo vs. Wegovy: How Do the New Weight Loss Pills Compare?: Each of these pills have been through extensive clinical trials and deliver similar numbers when ...
self.com/story/foundayo-vs-wegovy-glp-1-pills
Novo Nordisk cuts prices of Ozempic, Wegovy in India again to fend off generics competition
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-further-slashes-prices-ozempic-wegovy-india-better-compete-generics-2026-03-31/
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom: Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai ...
ndtv.com/health/ozempic-patent-expiry-heralds-weight-loss-drug-boom-in-india-11221001
Novo Nordisk's former chief makes comeback to steer choice of new CEO: Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster ...
reuters.com/sustainability/boards-policy-regulation/novo-nordisks-former-chief-makes-comeback-steer-choice-new-ceo-2025-05-22/
Lilly's weight-loss drug Zepbound to face supply crunch through April-end, US FDA says
reuters.com/business/healthcare-pharmaceuticals/some-doses-lillys-zepbound-short-supply-through-april-end-us-fda-says-2024-04-03/
Next